Remembering Those Who Could Not March

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

WASHINGTON--On the night before The March, as she waited for a candlelight vigil to begin, Ruth Kirkhuff talked about the son she lost to brain cancer and why she had journeyed here from Derry, New Hampshire. Matthew’s tumor was diagnosed at age 11 months, and he died Sept. 2, 1994. "We had a lot of ups and downs," she said. "Being here helps me keep his memory alive."

WASHINGTON--On the night before The March, as she waited for a candlelight vigil to begin, Ruth Kirkhuff talked about the son she lost to brain cancer and why she had journeyed here from Derry, New Hampshire. Matthew’s tumor was diagnosed at age 11 months, and he died Sept. 2, 1994. "We had a lot of ups and downs," she said. "Being here helps me keep his memory alive."

Several thousand people gathered in front of the Lincoln Memorial and along its lengthy reflecting pool. The mood and the faces were often solemn; the program almost a revival meeting in tone, with music and speeches, and the names of cancer victims flashing on screens beside the stage. "If we have the faith, God has the power," the Rev. Jesse Jackson said.

Cancer survivors appeared, including figure skating star Scott Hamilton, 7-year-old Morgan O’Brien, musician Herbie Mann, and the Rev. Thomas L. Walker, author of Brother to Brother: You Don’t Have to Die of Prostate Cancer.

But many found their greatest inspiration and solace in the people with whom they shared and exchanged stories. Theresa Mullens of Big Stone Gap, Va, has seen her mother and sister die of cancer. "I feel the cure could be found if we just had the resources," she said.

The cancer deaths of two friends and a brother-in-law (all within the last 4 years) and a desire to be with others who had suffered similar losses drew Bill Carney from Springfield, Va. He, too, spoke of getting increased funding for cancer. "I know there is not much an individual can do about it, but maybe in numbers...," he said, letting his thought trail off.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content